ArticleJAMA2016
Interventions for Vitiligo.
Article in JAMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Relative Impact of Monotherapies for Vitiligo: A Network Meta-Analysis Study.Journal of cosmetic dermatology · 2025Pooled it
- Meta-analysis of the efficacy of adding platelet-rich plasma to 308-nm excimer laser for patients with vitiligo.The Journal of international medical research · 2022Pooled it
- Current art of combination therapy with autologous platelet-rich plasma for stable vitiligo: A meta-analysis.International wound journal · 2021Pooled it
- Silymarin in combination with hair follicle transplantation as a potential treatment for refractory vitiligo: A double-blind randomized controlled trial.Journal of cosmetic dermatology · 2024Trial
- Assessment of Non-cultured Autologous Epidermal Cell Grafting Resuspended in Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism Lesions: A Randomized Clinical Trial.Acta dermato-venereologica · 2021Trial
- Trial
- Cytokine and Inflammasome Gene Polymorphisms in Vitiligo: A Candidate-Polymorphism Meta-Analysis.The Australasian journal of dermatology · 2026Article
- MSC-Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges-A Narrative Review.International journal of dermatology · 2026Review
- A 5-week low-dose prednisolone regimen for progressive vitiligo: efficacy and safety in a single-center cohort study.Annals of medicine · 2025Article
- Bioinformatics meets machine learning: identifying circulating biomarkers for vitiligo across blood and tissues.Frontiers in immunology · 2025Article
- Post-translational modification in the pathogenesis of vitiligo.Immunologic research · 2024Review
- [Quality of life, disease burden and healthcare need of patients with vitiligo].Dermatologie (Heidelberg, Germany) · 2024Review
- The impact of the COVID-19 surge on phototherapy in Taiwan: Focusing on the patient profile, adherence, and attitude before and after the surge.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023Article
- Review
- Diet and Vitiligo: The Story So Far.Cureus · 2022Review
- Association AmongClinical, cosmetic and investigational dermatology · 2022Article
- Vitiligo: What's old, what's new.Dermatology reports · 2021Article
- Current insight into the roles of microRNA in vitiligo.Molecular biology reports · 2020Review
- Home phototherapy for patients with vitiligo: challenges and solutions.Clinical, cosmetic and investigational dermatology · 2019Article
- Successful Treatment of Refractory Vitiligo with a Combination of Khellin and 308-nm Excimer Lamp: An Open-Label, 1-Year Prospective Study.Dermatology and therapy · 2018Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical Question: Which interventions are associated with highest efficacy and fewest adverse events for treating vitiligo? Bottom Line: Combination therapies, particularly those involving some form of light (ie, narrowband UV-B) were associated with more improved repigmentation than monotherapies. There was limited evidence to support the association of UV-A alone and UV-B alone with repigmentation for vitiligo. There was moderate evidence to support the association of UV-A and UV-B, when used in combination with psoralens, topical corticosteroids, vitamin D analogues, fluorouracil, azathioprine, and oral prednisolone with improved outcomes for vitiligo. However, combination therapies were associated with more adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.